^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EML4-ALK fusion

    i
    Entrez ID:
    238; 27436
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China (NCT03909971)
    Phase 2
    Pfizer
    Active, not recruiting
    Last update posted :
    02/21/2024
    Initiation :
    04/28/2019
    Primary completion :
    08/10/2020
    Completion :
    12/31/2024
    EML4
    |
    ALK positive • EML4-ALK fusion • ALK fusion
    |
    Lorbrena (lorlatinib)
    The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring (NCT04499794)
    Phase N/A
    Chinese Academy of Medical Sciences
    Recruiting
    Last update posted :
    08/05/2020
    Initiation :
    08/01/2020
    Primary completion :
    07/31/2024
    Completion :
    03/31/2025
    EML4
    |
    EML4-ALK fusion • ALK fusion
    Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors (NCT01803282)
    Phase 1
    Gilead Sciences
    Completed
    Last update posted :
    06/02/2020
    Initiation :
    03/29/2013
    Primary completion :
    04/23/2019
    Completion :
    04/23/2019
    HER-2 • ALK • EML4
    |
    EGFR mutation • HER-2 negative • EML4-ALK fusion • ALK fusion • ALK translocation
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • andecaliximab (GS-5745)
    Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 (NCT03158324)
    Phase 2a
    National University Hospital, Singapore
    Unknown status
    Last update posted :
    06/15/2017
    Initiation :
    05/22/2017
    Primary completion :
    05/22/2020
    Completion :
    11/30/2020
    EGFR • BRAF • ALK • EML4 • SIRT1
    |
    EGFR mutation • BRAF mutation • ALK positive • EML4-ALK fusion • ALK fusion • ALK mutation • RET mutation
    |
    OPB-111077
    An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene (NCT00932893)
    Phase 3
    Pfizer
    Completed
    Last update posted :
    01/02/2017
    Initiation :
    09/01/2009
    Primary completion :
    03/01/2012
    Completion :
    01/01/2016
    ALK • MET • EML4 • HGF
    |
    ALK positive • EML4-ALK fusion • ALK fusion
    |
    Xalkori (crizotinib) • docetaxel • pemetrexed